Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 945

1.

Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S.

Cochrane Database Syst Rev. 2018 Sep 24;9:CD011798. doi: 10.1002/14651858.CD011798.pub2. Review.

PMID:
30246878
2.

The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.

Ling J, Cheng P, Ge L, Zhang DH, Shi AC, Tian JH, Chen YJ, Li XX, Zhang JY, Yang KH.

Acta Diabetol. 2018 Sep 21. doi: 10.1007/s00592-018-1222-z. [Epub ahead of print] Review.

PMID:
30242726
3.

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.

Otowa-Suematsu N, Sakaguchi K, Nakamura T, Hara K, Kishi M, Hashimoto N, Yokota K, Yoshino H, Kuroki Y, Nishiumi T, Sou A, Komada H, Okada Y, Hirota Y, Tamori Y, Ogawa W.

Diabetes Ther. 2018 Oct;9(5):2067-2079. doi: 10.1007/s13300-018-0505-2. Epub 2018 Sep 11.

4.

Identification of a novel metabolite of vildagliptin in humans: Cysteine targets the nitrile moiety to form a thiazoline ring.

Mizuno K, Takeuchi K, Umehara K, Nakajima M.

Biochem Pharmacol. 2018 Oct;156:312-321. doi: 10.1016/j.bcp.2018.08.043. Epub 2018 Aug 31.

PMID:
30172711
5.
6.

A comparison of the anti-diabetic potential of d-ribose-l-cysteine with insulin, and oral hypoglycaemic agents on pregnant rats.

Osinubi AAA, Medubi LJ, Akang EN, Sodiq LK, Samuel TA, Kusemiju T, Osolu J, Madu D, Fasanmade O.

Toxicol Rep. 2018 Aug 9;5:832-838. doi: 10.1016/j.toxrep.2018.08.003. eCollection 2018.

7.

Vildagliptin Enhances Differentiation of Insulin Producing Cells from Adipose-Derived Mesenchymal Stem Cells.

Karimi S, Ai J, Khorsandi L, Bijan Nejad D, Saki G.

Cell J. 2019 Jan;20(4):477-482. doi: 10.22074/cellj.2019.5542. Epub 2018 Aug 1.

PMID:
30123993
8.

Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios.

Gomez-Peralta F, Abreu C, Gomez-Rodriguez S, Barranco RJ, Umpierrez GE.

Diabetes Ther. 2018 Oct;9(5):1775-1789. doi: 10.1007/s13300-018-0488-z. Epub 2018 Aug 16. Review.

9.

Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial.

Cosenso-Martin LN, Giollo-Júnior LT, Fernandes LAB, Cesarino CB, Nakazone MA, de Nassau Machado M, Yugar-Toledo JC, Vilela-Martin JF.

Acta Diabetol. 2018 Aug 9. doi: 10.1007/s00592-018-1204-1. [Epub ahead of print]

PMID:
30094725
10.
12.
13.

Combination of Vildagliptin and Ischemic Postconditioning in Diabetic Hearts as a Working Strategy to Reduce Myocardial Reperfusion Injury by Restoring Mitochondrial Function and Autophagic Activity.

Bayrami G, Alihemmati A, Karimi P, Javadi A, Keyhanmanesh R, Mohammadi M, Zadi-Heydarabad M, Badalzadeh R.

Adv Pharm Bull. 2018 Jun;8(2):319-329. doi: 10.15171/apb.2018.037. Epub 2018 Jun 19.

14.

Neuroprotective effect of vildagliptin against cerebral ischemia in rats.

El-Marasy SA, Abdel-Rahman RF, Abd-Elsalam RM.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Oct;391(10):1133-1145. doi: 10.1007/s00210-018-1537-x. Epub 2018 Jul 18.

PMID:
30022232
15.

Impact of treatment with glibenclamide or vildagliptin on glucose variability after aerobic exercise in type 2 diabetes: A randomized controlled trial.

Fofonka A, Bock PM, Casali KR, da Silveira AD, da Rosa FM, Berlanda G, Schaan BD.

Diabetes Res Clin Pract. 2018 Sep;143:184-193. doi: 10.1016/j.diabres.2018.07.007. Epub 2018 Jul 7.

PMID:
29990565
16.

Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.

Parthan G, Bhansali S, Kurpad AV, Walia R, Bhat K, Bhansali A.

BMC Pharmacol Toxicol. 2018 Jul 3;19(1):38. doi: 10.1186/s40360-018-0228-z.

17.
18.

A Possible Mechanism: Vildagliptin Prevents Aortic Dysfunction through Paraoxonase and Angiopoietin-Like 3.

Zhang Q, Xiao X, Zheng J, Li M, Yu M, Ping F, Wang T, Wang X.

Biomed Res Int. 2018 May 23;2018:3109251. doi: 10.1155/2018/3109251. eCollection 2018.

19.

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.

Ayoub BM, Mowaka S, Safar MM, Ashoush N, Arafa MG, Michel HE, Tadros MM, Elmazar MM, Mousa SA.

Sci Rep. 2018 Jun 12;8(1):8959. doi: 10.1038/s41598-018-27395-0.

20.

Vildagliptin, a DPP4 inhibitor, alleviates diabetes-associated cognitive deficits by decreasing the levels of apoptosis-related proteins in the rat hippocampus.

Zhang DD, Shi N, Fang H, Ma L, Wu WP, Zhang YZ, Tian JL, Tian LB, Kang K, Chen S.

Exp Ther Med. 2018 Jun;15(6):5100-5106. doi: 10.3892/etm.2018.6016. Epub 2018 Apr 2.

Supplemental Content

Loading ...
Support Center